Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across biomedical AI, cancer, cardiovascular diseases, inflammation, immunity, age-related, rare and infectious diseases.

          Learn more

        • Biomedical AI
        • Cancer Innovations
        • Cardiovascular Research
        • Healthy Ageing
        • Infection & Immunity
        • Inflammation
        • Rare Diseases & Gene Therapy
        • Laboratories
        • Diseases
        • Expertises
        • Breakthroughs
        • Technologies
          • Clinical Translation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
        • Community and research
  • Careers & students
        • Careers & Students

          Postdoctoral and postgraduate students can work alongside world-leading medical researchers within state-of-the-art research facilities.

        • Career Opportunities
        • Student Opportunities
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
          • Healthy Recipes
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
          • Statements
        • Real stories
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
          • Animals in research
        • Contact
  • Donate
    Centenary Institute > News > New method to assist fast-tracking of vaccines for pre-clinical tests

New method to assist fast-tracking of vaccines for pre-clinical tests

Date time 18 January, 2021
News Type News type Research News
Scientists in Australia have developed a method for the rapid synthesis of safe vaccines, an approach that can be used to test vaccine strategies against novel pandemic pathogens such as SARS-CoV-2, the virus that causes COVID-19.Ê

Scientists in Australia have developed a method for the rapid synthesis of safe vaccines, an approach that can be used to test vaccine strategies against novel pandemic pathogens such as SARS-CoV-2, the virus that causes COVID-19. 

Led by Professor Richard Payne at the University of Sydney and Professor Warwick Britton (pictured) at the Centenary Institute, the team has demonstrated application of the method with a new vaccine for use against tuberculosis (TB), which has generated a powerful protective immune response in mice. 

Researchers are keen to develop the vaccine strategy further to assist in the rapid pre-clinical testing of new vaccines, particularly for respiratory illnesses. 

“Tuberculosis infects 10 million and kills more than 1.4 million people every year,” said joint first author Dr Anneliese Ashhurst from the University of Sydney. “Historically, it is the leading cause of death worldwide from a single infectious agent. So far, a TB vaccine that is highly effective and safe to use in all populations has eluded medical science.” 

The only current vaccine for tuberculosis, the Bacille Calmette-Guerin vaccine, uses an injected live bacterium. It is effective in infants but has reduced effectiveness in adolescents and adults and poses significant health risks for immunocompromised patients, particularly for people living with HIV/AIDS. 

Protein-based vaccines have been shown to be very safe, but they must be mixed with enhancers, or adjuvants, to make them effective, which is not straightforward. 

Dr Ashhurst said: “The challenge is to ensure that our immune cells see both the protein and adjuvant simultaneously. To overcome this difficulty, for the first time we have developed a method that synthesises the protein with an attached adjuvant as a single molecule.” 

The vaccine strategy and synthetic technology could be deployed to rapidly generate new vaccines for pre-clinical testing for a range of diseases, the researchers say, including the respiratory pathogen that causes COVID-19. 

Their results are published today in the Proceedings of the National Academy of Sciences of the United States of America. 

HOW IT WORKS 

In order for vaccines to be effective, they need to stimulate behaviour in protective T-cells that allows them to recognise the pathogen as an antigen, or foreign body. In the case of tuberculosis, our immune system needs to respond quickly to the bacteria that causes TB – Mycobacterium tuberculosis – to reduce infection in lungs. 

Using the method developed by the Sydney scientists, an inhaled vaccine provides a low-dose immune-stimulating molecule – containing a synthesised bacterial protein attached directly to an adjuvant – to the immune cells in the lungs. 

A major hurdle overcome by the scientists was the difficulty in fusing hydrophobic (water-repellent) adjuvants with a water-soluble protein antigen. 

“We got around this problem of keeping hydrophobic and hydrophilic molecules together in a vaccine by developing a way to permanently bind the protein and adjuvant together as a single molecule using synthetic chemistry. Our approach overcomes the solubility problems faced by other methods,” said Professor Payne from the School of Chemistry and Deputy Director of the ARC Centre for Innovations in Peptide & Protein Science (CIPPS). 

The team says that synthesising an entire bacterial protein with attached adjuvant has not been achieved before. 

Professor Britton from the Tuberculosis Research Program at the Centenary Institute said: “As well as providing a rapid method to develop a range of vaccines for pre-clinical testing, we expect that this pulmonary vaccination approach will be particularly beneficial for protecting against respiratory diseases.” 

He said: “We hope that an inhaled vaccine for tuberculosis using a protein-based immunisation will allow us to develop a universal and safe approach to combatting this deadly disease.” 

The other major advantage with this method is that vaccines for a range of diseases can be developed rapidly and safely in the laboratory. 

“We don’t need to grow the actual pathogen in the lab to make the vaccine,” said Dr Ashhurst, who holds a joint position in the School of Chemistry and the School of Medical Sciences. “Using this new method, we can rapidly and safely synthesise highly pure vaccines in the lab and take them straight into animal models for pre-clinical testing.” 

Research paper: Synthetic protein conjugate vaccines provide protection against Mycobacterium tuberculosis in mice.

Read more about the Centenary Institute’s TB related medical research here.

Themes

  • Inflammation

    Inflammation

Laboratories

  • Britton

Media enquires

For all media and interview enquiries, please contact Alison Mendel

Phone number Phone Number +61 434 629 469

Email Email a.mendel@centenary.org.au

Recent Stories

  • New platform to evolve proteins for better therapies

    Researchers from the Centenary Institute, in collaboration with the University of Sydney, have developed a powerful new tool to evolve proteins directly within mammalian cells, offering a more effective way to design medical treatments tailored to the human body.
    News Type: Media release
    Date 08 May 2025
  • Turning off protein may help prevent liver cancer

    New research from the Centenary Institute has found that switching off a specific protein in liver cells may help prevent the early development of liver cancer.
    News Type: Media release
    Date 16 Apr 2025
  • Event shines spotlight on genetic heart disease in young people

    The Centenary Institute has hosted a community event, titled ‘A Needle in a Haystack: Unlocking the Secrets of Genetic Heart Conditions’. The event aimed to advance understanding of inherited heart disease and sudden cardiac death in young people.
    News Type: Community
    Date 10 Apr 2025
  • Finding answers for sudden cardiac death in young people

    Each week in Australia, up to three young people die suddenly and unexpectedly from sudden cardiac death, often due to an undiagnosed genetic heart condition. These conditions typically go unnoticed until tragedy strikes, leaving families devastated and searching for answers.
    News Type: Media release
    Date 02 Apr 2025

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram